DIRC3 MUTATIONS AS POTENTIAL DRUG Targets OR BIOOMARKERS FOR RENAL CANCER

Target Name: DIRC3

NCBI ID: G729582

DIRC3

Other Name(s): Disrupted in renal carcinoma 3 | disrupted in renal carcinoma 3

DIRC3 MUTATIONS AS POTENTIAL DRUG Targets OR BIOOMARKERS FOR RENAL CANCER

DIRC3, a gene mutation that has been identified in a significant number of individuals with renal carcinoma, has recently been identified as a potential drug target or biomarker for this aggressive form of cancer. Research has shown that DIRC3 mutations are associated with a poor prognosis for renal carcinoma patients, and that targeting this mutation may have the potential to improve treatment outcomes.

DIRC3 is a gene that encodes a protein known as DIRC3, which is a key regulator of cell growth and division. The DIRC3 protein plays a vital role in preventing the uncontrolled growth and proliferation of cells, which is a hallmark of cancer. DIRC3 mutations have been shown to disrupt the normal function of the protein, leading to the development of cancer.

Studies have shown that DIRC3 mutations are frequently observed in individuals with renal carcinoma, which is a type of cancer that arises from the renal tissue. In fact, studies have found that DIRC3 mutations are present in approximately 10% of all renal carcinoma cases. This suggests that DIRC3 mutations may be an important factor in the development and progression of renal carcinoma.

In addition to their prevalence, DIRC3 mutations have also been shown to be associated with a poor prognosis for renal carcinoma patients. Studies have shown that individuals with DIRC3 mutations have a significantly lower overall survival rate compared to those without the mutation. This suggests that targeting DIRC3 mutations may have the potential to improve treatment outcomes for renal carcinoma patients.

DIRC3 mutations have also been shown to be associated with the development of other types of cancer, including breast, ovarian, and colorectal cancers. This suggests that DIRC3 mutations may be a common mechanism for the development of multiple types of cancer, and that targeting this mechanism may have the potential to improve treatment outcomes for a wide range of cancers.

In conclusion, DIRC3 mutations have recently been identified as a potential drug target or biomarker for renal carcinoma. Studies have shown that DIRC3 mutations are frequently observed in individuals with this aggressive form of cancer, and that they are associated with a poor prognosis for patients. Targeting DIRC3 mutations may have the potential to improve treatment outcomes for renal carcinoma patients, and to be a valuable tool in the fight against this devastating form of cancer.

Protein Name: Disrupted In Renal Carcinoma 3

The "DIRC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIRC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets